



Partner

Fumi Takatsuki

Osaka Bar Association, Japan Federation of Bar Associations (2000) Location Osaka Office

Practice Areas

Corporate and M&A

General Corporate Practice

Risk Management & Compliance

Corporate Investigation / Global Compliance / Product Liability

Dispute Resolution

International Dispute Resolution / Corporate Litigations, Disputes and D&O Liabilities

International Practice

International Commercial Contracts / Chinese Practice / Trade Remedies (Anti-Dumping, Countervailing Duties and Safeguards) / International Dispute Resolution

Competition and Antitrust/Consumer Protection

Competition/Consumer Protection Counseling

Life Science, Pharmaceutical and Healthcare

Research and Development / Marketing Regulation / Labelling and Advertising regulation / Crisis Management / M&A / Cosmetics & Health/Beauty Care Products

Education & Professional Experience

2009 - present Partner, Oh-Ebashi LPC & Partners

2006 - present Oh-Ebashi LPC & Partners

2004 - 2005 Anderson Mori & Tomotsune Beijing Office

Anderson Mori & Tomotsune

2003

Oike Law Office

1998-1999 Language study at the Central Academy of Drama in Beijing

1998

Publications

2025.09.25	Legal Affairs for Chinese Life Sciences and Healthcare No. 25: Update on the Amendments to China 's Medical Device Laws and Regulations
2025.05.27	Legal Affairs for Chinese Life Sciences and Healthcare No. 24: Update on the Revisions to Chinese Pharmaceutical Regulations
2025.03.24	Legal Affairs for Chinese Life Sciences and Healthcare No. 23: Updates on the Amendments of Pharmaceutical Laws and Regulations of China
2024.09.26	Legal Affairs for Chinese Life Sciences and Healthcare No. 22: Shanghai Cosmetics Industry Advertising Compliance Guidelines
2024.01.24	Legal Affairs for Chinese Life Sciences and Healthcare No. 21: Revision to the Administrative Regulation on Wholesale, Retail, etc., of Pharmaceutical Products (Establishment of the Regulation on Supervision and Administration of Business Management and Quality of Pharmaceutical Products)
2023.11.28	Legal Affairs for Chinese Life Sciences and Healthcare No. 20: Notice on Enhancing the Supervision and Administration of Contract Manufacture of Drug Marketing Authorization Holders (No. 132 of 2023)
2023.10.27	Publication of the Draft Revisions to the Product Quality Law of China
2023.08.28	Obligation to Establish a Quality and Safety Management System in China
2023.07.25	Legal Affairs for Chinese Life Sciences and Healthcare No.19: Handling and Transborder Transfer of Human Genetic Resources and Information in Chinese Domestic Clinical Trials and Scientific Research
2023.05.24	Legal Affairs for Chinese Life Sciences and Healthcare No.18: Enactment of Regulations on Toothpaste in China
2023.03.28	Legal Affairs for Chinese Life Sciences and Healthcare No.17: Enforcement of the Rules for Responsible Supervision and Management of Quality and Safety Enforcement Entities for Drugs, Cosmetics and Medical Devices
2023.02.28	Legal Affairs for Chinese Life Sciences and Healthcare No.16: Rejection of UCB Pharma S.A. and GlaxoSmithKline (Ireland) Limited in the Extraterritorial Off-Site Inspection
2023.02.27	China 's Life Science and Healthcare-No.3 Amendment of the Regulations on Cosmetics in China
2023.01.20	Legal Affairs for Chinese Life Sciences and Healthcare No.15: System of the Person Responsible for the Production Safety (Safety Officer) of Food and Food-related Products in China
2022.11.29	Legal Affairs for Chinese Life Sciences and Healthcare (Part 14) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
2022.10.25	Legal Affairs for Chinese Life Sciences and Healthcare (Part 13) -Chinese Regulations on Labeling and Advertisement for Cosmetics-
2022.07	Theory and Practice of Chinese Commercial Dispute Resolution (27) Consumer Contracts and Arbitration Clauses
2022.07.04	China 's Life Sciences and Healthcare-No.2 - The Good Vigilance Practice rule in China
2022.05.26	Legal Affairs for Chinese Life Sciences and Healthcare (Part 10) - Toward the Enforcement of the New Cosmetics GMP
2022.03.24	Legal Affairs for Chinese Life Sciences and Healthcare (Part 8) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (3)
2022.03.14	A Legal Review of China 's Life Sciences and 2 Healthcare- No.1 - General Introduction and MAH System
2022.02.21	Legal Affairs for Chinese Life Sciences and Healthcare (Part 7) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on

2022.01.25	Employment and Immigration Law Guide 2022 Jurisdiction:Japan
2022.01.21	Legal Affairs for Chinese Life Sciences and Healthcare (Part 5) - Amendment to the Cosmetic Supervision and Administration Regulation for the First Time in 30 Years, and the Subsidiary Regulations on Administrative Measures for Cosmetic Registration, the Subsidiary Regulations on Administration Measures for Cosmetics Manufacture and Operation and the GMP for Cosmetics (1)
2021.11.24	Legal Affairs for Chinese Life Sciences and Healthcare (Part 4) – Developments in Amendment of Regulations Concerning Wholesaling/Retailing of Pharmaceutical Products, Etc. (Measures on Supervision and Control of the Drug Business and Usage Quality (Draft for Comment))
2021.10.28	Legal Affairs for Chinese Life Sciences and Healthcare (Part 3) – Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (2)
2021.09.30	Legal Affairs for Chinese Life Sciences and Healthcare (Part 2) –Approaching the implementation of China GVP (Good Pharmacovigilance Practice) (effective from December 1, 2021) (1)
2021.08.30	Legal Affairs for Chinese Life Sciences and Healthcare
2019.10	Points to Consider Regarding Advertising Expressions when Doing Business in China
2019.05	Case Study on Court Judgement in China Regarding Recognition and Enforcement of Foreign or External Arbitral Award
2018.12	Acts against Unjustifiable Advertisement and Misleading Representations in China
2018.04	Case Study on Court Judgment in China Regarding Recognition and Enforcement of Foreign Arbitral Award (14)
2017.12	100 Selected Cases in China, Series 250
2017.07	Office 40s: Business Legal Affairs: Theory and Practice regarding Civil and Commercial Laws in China [113]
2016.11	Recent Developments in Chinese Business Law, No. 50: Toward an Improved Cooling-off System
2016.08	100 Selected Cases in China, Series 234: A Case where the Court Recognized and Enforced an Award in a Foreign Arbitration between Chinese Domestic Companies Concerning Domestic Trade in China
2016.03	Latest Updates on Chinese Business Legal Affairs, 43rd Series: Draft Leniency Guidelines and Approval System Guidelines under the Antitrust Law of China
2016.03	Recent Developments in Chinese Business Law, No. 43: Draft Guidelines on the Leniency and Approval System under the Anti-monopoly Law of China
2015.11	100 Selected Cases in China, Series 225: A Case Involving the Copyrightable Nature of the Production of Match-up Games in an Online Battle Game
2015.08	Latest Updates on Chinese Business Legal Affairs, 36th Series: Ad-hoc Arbitrations and Relevant Practices in China
2015.05	Transcript of Lectures: Seminar on Issues concerning Arbitration Practices in China (2)
2015.04	Transcript of Lectures: Seminar on Issues concerning Arbitration Practices in China (1)
2015.02	Is an Agreement Requiring Arbitration In China by a Foreign Arbitration Body Valid?
2014.11	100 Selected Cases in China, 213th Series: A Case Involving the Liability of a Proprietor of an Online Shopping Mall for the Sale of Articles Infringing Trademark Rights
2014.11	Latest Updates on Chinese Business Legal Affairs, 29th Series: Current Risks of Non-Compliance in China and Penalties Therefor - GSK China's Commercial Bribery Case where a 53 Billion Yen Fine was Imposed
2014.03	Latest Updates on Chinese Business Legal Affairs, 22nd Series: Reformation of the Registered Capital

2014.02	Collection of Claims and Information Disclosure by Courts in China
2013.08	Latest Updates on Chinese Business Legal Affairs, 15th Series: Latest Updates on the CIETAC Spin Off Issue
2013.03	100 Selected Cases in China, 193rd Series: The Case Dismissing Apple's Claim for Confirmation of the Attribution of Trademark Rights to the iPad
2012.11	Latest Updates on Chinese Business Legal Affairs, 8th Series: Promulgation of the Tertiary Guiding Cases Determined by the Supreme People's Court
2011.12	100 Selected Cases in China, 178th Series: The Case where the Judgment Upheld a Claim for Indemnification of Damages and Return of Unjust Enrichment concerning Abuse of Shareholders' Right
2011.06.15	Feature Article: On the Current Enforcement under the Antitrust Law in China - Practical Considerations on Antitrust Law in China
2010.12	Current Legal Risks and Considerations concerning Business in China as an Audit & Dervisory

System in China

Board Member

Seminars/Lectures

2025.07.14	Overview of/Law Amendment Information concerning the Latest Medical Device Regulations in China, and Related Requirements 2025
2025.03.13	[Online Seminar] Overview of/Law Amendment Updates concerning the Latest Medical Device Regulations in China 2025
2024.05.23	[Online Seminar] Overview of/Law Amendment Updates concerning the Latest Medical Device Regulations in China 2024
2024.02.02	Japan China Economic Relations and Trade Centre Professional Lecture No. 97: "Trends in the Amendment of the Product Quality Law of China"
2023.06.16	[Online Seminar] Latest Medical Device Regulations in China 2023
2022.12.16	[Online Seminar] Latest on the Chinese Pharmaceutical and Cosmetics Industries 2022
2022.12.12 ~ 2023.02.12	[Online Seminar: Video Streaming] Life Science Practice Seminar No.9: Life Science Issues in China - Updates on Amendment of the Chinese Pharmaceutical Affairs Law, and Regulations on Efficacy Claims and Extravagant Advertisements of Cosmetics in China
2022.12.09	【Onilne Seminar】 Life Science Practice Seminar No.9: Life Science Issues in China - Updates on Amendment of the Chinese Pharmaceutical Affairs Law, and Regulations on Efficacy Claims and Extravagant Advertisements of Cosmetics in China
2022.03.02	【Online Seminar 】Seminar on Life Science in China: Basics of Drug Restrictions in China (2022) - Law Amendments Regarding the Compliance Structures Including the MAH System, Registration and Management of MRs and GVP and Actions to Take
2021.01.25 ~ 2021.04.23	[Online Seminar: Video Streaming] China Legal Practice Update
2021.01.15 ~ 2021.04.09	[Online Seminar: Video Streaming] China Legal Practice Update
2020.12.15 ~ 2021.02.12	[Online Seminar: Video Streaming] China Legal Practice Update

Languages

Japanese, English & Chinese